Patient safety and compliance are top priorities! Cadila Pharmaceuticals again clear role, know in detail

MUMBAI: Cadila Pharmaceuticals, a research-based pharmaceutical company, has reiterated its commitment to patient safety following recent regulatory interactions regarding its Aciloc range. The company reiterated that the Active Pharmaceutical Ingredient (Active Pharmaceutical Ingredient) has always been clearly and prominently mentioned on the packaging and labels of all Aciloc products as per applicable regulatory requirements. The company’s scientific and regulatory teams are conducting a detailed study of the matter in coordination with the concerned authorities.(Photo Courtesy – AI)

Recognize the symptoms of liver cancer in time! Include these foods in your diet to get rid of liver diseases

Chairman of Cadila Pharmaceuticals Limited Dr. Arani Chatterjee said, “Patient safety is our top priority. As per the applicable regulatory requirements, the active medicinal ingredient is clearly stated on each Aciloc pack. We are working closely with the relevant authorities, providing full cooperation and carefully reviewing the matter. We are committed to maintain confidence in the quality, safety and appropriate use of our medicines.”

The company further clarified that Aciloc 150+ and Aciloc 300+ fall under the same therapeutic group of H2 receptor antagonists, and their respective active ingredients are clearly mentioned on each pack as per regulatory requirements. Cadila Pharmaceuticals has been a pioneer in the Indian healthcare industry for over 75 years. The company is developing high quality and affordable medicines by adhering to applicable regulatory standards, robust quality systems and ethical business practices. Cadila Pharmaceuticals reiterated that it is committed to maintaining the highest standards of quality, patient safety and regulatory compliance and will continue to work constructively with the relevant authorities.